FDA: Pfizer's Lyrica GAD Data Insufficient
Pfizer said late Wednesday it has been told by regulators that the data submitted in its application for the use of its drug Lyrica as a stand-alone treatment for generalized anxiety disorder were insufficient to gain approval. The Food and Drug Administration's decision came after Pfizer (PFE) resubmitted its application in response to a "not-approvable" letter issued by the FDA in August 2004. The FDA is still reviewing a separate application
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here